Femasys stock.

Latest Femasys News: View FEMY news and discuss market sentiment with the investor community on Public.com.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Femasys share forecasts, stock quote and buy / sell signals below. According to present data Femasys's FEMY shares and potentially its market environment have been in bearish cycle last 12 months (if exists).- The 510(k) Clearance from the United States Food and Drug Administration (FDA) allows for the U.S. commercialization of FemaSeed ®, an intratubal artificial insemination option designed to augment the natural fertilization process - - FemaSeed ® is an innovative infertility treatment designed to deliver sperm directly to where conception …Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...

Electronic Technology. Industry. Electronic Equipment/Instruments. No executives to display. Corporate headquarters. --, --. Find real-time FEMY - Femasys Inc stock quotes, company profile, news ...Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ...

Femasys was previously notified by Nasdaq on June 1, 2023 that it was not in compliance with the minimum bid price rule (“the Rule”) because its common stock failed to meet the closing bid ...Portfolio Overview. Our non-surgical, proprietary delivery platform requires no capital equipment and leverages existing intrauterine techniques. Our minimally invasive technologies are designed to provide safe, convenient in-office approaches, saving time and reducing costs. Femasys has an expansive, internally-created intellectual property ...

Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 13.36% for FEMY.Femasys Inc. 2021 Employee Stock Purchase Plan, incorporated by reference to Exhibit 10.4 of the registrant’s Form S-1 filed May 14, 2021 10.3 Amended and Restated Employment Agreement, by and between Femasys Inc. and Kathy Lee-Sepsick, incorporated by reference to Exhibit 10.6 of the registrant’s Form S-1/A filed June 14, 2021Description. Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient ... The downside is that many penny stocks are active for no good fundamental reason and have only volatility to offer investors. FEMY’s Market Performance. Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter.ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …

Femasys Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 27, 2023 5:01 p.m. EST Delayed quote $ 1.0500 0.02 1.94% After Hours Volume: 21.5K Advanced …Web

Oct 26, 2023 · Oct. 26, 2023, 08:30 AM. – Completion of the European Union Medical Device Regulation (MDR) final audit is the last step in obtaining an MDR certificate and CE marking, confirming Femasys ...

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the …Oct 2, 2023 · What To Know: HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has ... SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/30/2023. S-3. Securities Registration Statement (simplified form) 11/29/2023. 8-K. Current report filing.Ratings analysis incomplete due to data availability. Recommendations not provided. Maximize Income Goal. See Best High Dividend Stocks Model Portfolio for our ...Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerWebGet daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.

LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions ... Dec 2, 2023 · Femasys Inc (NASDAQ:FEMY) trade information. Femasys Inc (FEMY) registered a -2.33% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.33% in intraday trading to $0.93 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -9.71%, and it has moved by -33.09% in ... Femasys Inc (FEMY) has experienced a 3.06% rise in stock performance for the past week, with a -36.36% drop in the past month, and a 113.56% rise in the past quarter. The volatility ratio for the week is 11.20%, and the volatility levels for the past 30 days are at 13.36% for FEMY.Historical Stock Quote. Investment Calculator. Amount ($) Start Date: End Date: Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate Investment. ... At Femasys Inc., we promise to treat your data with respect and will not share your information with any third party.Femasys Stock Earnings. The value each FEMY share was expected to gain vs. the value that each FEMY share actually gained. Femasys ( FEMY) reported Q3 2023 earnings per share (EPS) of -$0.26, missing estimates of -$0.22 by 21.75%. In the same quarter last year, Femasys 's earnings per share (EPS) was -$0.25. Femasys is expected to release next ...Grading Femasys Inc Stock. Before you choose to buy, sell or hold Femasys Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.

ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide …Web

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Femasys Inc. (FEMY) Add to watchlist. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 1.0300 +0.1162 (+12.72%) At close: …In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.Oct 2, 2023 · Femasys Inc, a medical technology company, has been attracting attention from investors due to its positive stock performance on October 2, 2023. According to data from CNN Money, the company has received favorable price forecasts from four analysts, with a median target of $8.50. The high estimate is $13.00, while the low estimate is $5.00. Femasys Inc ( FEMY) has fallen Tuesday morning, with the stock losing -1.54% in pre-market trading to 1.28. FEMY's short-term technical score of 47 indicates that the stock has traded less bullishly over the last month than 53% of stocks on the market. In the Medical Instruments & Supplies industry, which ranks 80 out of 146 industries, Femasys ...Nov 18, 2023 · Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81. In a concurrent private placement, Femasys has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 3,196,722 shares of common stock.Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p.m. ET to 3:30 p.m. ET of the following day.Femasys saw a decline in short interest in November. As of November 15th, there was short interest totaling 286,700 shares, a decline of 33.0% from the previous total of 427,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will ...

Short interest for Femasys gives investors a sense of the degree to which investors are betting on the decline of Femasys's stock. Short interest data is updated every two weeks.

Femasys (FEMY) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Femasys. The company’s shares closed last Wednesday at $1.11.

Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including FemaSeed ® an FDA- cleared infertility treatment, FemBloc ® a lead late-clinical stage product candidate for permanent birth control, and FDA-cleared, innovative diagnostic products.PR Newswire — Thinking about buying stock in Ardelyx, Rivian Automotive, Femasys, Lucid Group, or Outlook Therapeutics? News • Oct 11, 2023 Morningstar — Femasys Inc. Regains Compliance with Nasdaq Listing RequirementsNov 24, 2023 · Femasys Inc (NASDAQ: FEMY) has seen a rise in its stock price by 1.31 in relation to its previous close of 0.90. However, the company has experienced a -9.52% decline in its stock price over the last five trading sessions. MarketBeat reported 2023-10-05 that Penny stocks can be a treasure trove of investment opportunities, and […] Our Vision. Femasys is working to provide next generation advancements to disrupt severely under-served areas in women’s health. Technological advancements in female reproductive health are long overdue, driving our focus in permanent birth control and front-end infertility. HC Wainwright & Co. analyst Emily Bodnar maintained Femasys with a Buy rating and raised the price target from $5 to $13 on Friday. Femasys also announced last week that it has activated enrollment for its FemBloc trial to investigate a permanent birth control candidate. Shares of FEMY are moving higher on very heavy trading volume.Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.Check Out Our Latest Research Report on Femasys. Femasys Stock Performance. NASDAQ:FEMY opened at $0.96 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.28 and a current ratio of 4.68. The firm’s 50-day moving average is $1.25 and its 200-day moving average is $0.81.Femasys’ FemBloc ® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for ...

... Stock quotes by finanzen.net · Home · Stocks · Femasys-stock · News for Femasys Femasys. News for Femasys Inc Registered Shs. TipRanks 10d. Femasys (FEMY): ...Get the latest Femasys Inc. (FEMY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Femasys Inc (FEMY) stock is trading at $1.10 as of 10:08 AM on Wednesday, Nov 15, an increase of $0.17, or 18.28% from the previous closing price of $0.93. The stock has traded between $1.05 and $1.25 so far today. Volume today is 2,748,419 compared to average volume of 3,456,068.Instagram:https://instagram. dividend per share calculatorimmediate health insurance texasarcbcheap stocks Femasys Inc FEMY shares surged after the company received FDA 510 (k) clearance for FemaSeed, an infertility treatment designed to deliver sperm directly to where conception occurs in a woman's fallopian tube. Infertility has affected an increasing number of women – estimated at 10 million in the U.S., according to the Center for Disease Control.Femasys Stock Earnings. The value each FEMY share was expected to gain vs. the value that each FEMY share actually gained. Femasys ( FEMY) reported Q3 2023 earnings per share (EPS) of -$0.26, missing estimates of -$0.22 by 21.75%. In the same quarter last year, Femasys 's earnings per share (EPS) was -$0.25. Femasys is expected to release next ... robin hood cash sweepiso tokens View live Femasys Inc. chart to track its stock's price action. Find market predictions, FEMY financials and market news. ... Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare.Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Femasys Inc have a median target of 8.50, with a high estimate of 12.00 and a low estimate of 5.00. The median estimate ... perfectcorp Aug 10, 2023 · Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update. August 10, 2023 08:00 ET ... Common stock, $.001 par, 200,000,000 authorized, ... Femasys Inc. (NASDAQ: FEMY) shares are trading higher Friday after HC Wainwright maintained a Buy rating on the stock and raised its price target from $5 to $13.Nov 27, 2023 · What is Femasys's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Femasys stock is Buy based on the current 3 buy ratings for FEMY. The average twelve-month price prediction for Femasys is $9.00 with a high price target of $10.00 and a low price target of $7.00.